Month: November 2022

On November 30, 2009, Concellon, Carmen; Duguet, Nicolas; Smith, Andrew D. published an article.Reference of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one The title of the article was N-Heterocyclic Carbene-Mediated Enantioselective Addition of Phenols to Unsymmetrical Alkylarylketenes. And the article contained the following:

Chiral N-heterocyclic carbenes (NHCs) mediate the enantioselective addition of 2-phenylphenol to unsym. alkylarylketenes, delivering α-alkyl-α-arylacetic acid derivatives with good levels of enantiocontrol (up to 84% ee). Enantiodivergent stereochem. outcomes are observed using 2-phenylphenol and benzhydrol in the NHC-promoted esterification reaction using a triazolium precatalyst derived from pyroglutamic acid, consistent with distinct mechanistic pathways operating within these processes. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Reference of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one

The Article related to addition stereoselective phenol alkylarylketene n heterocyclic carbene catalyst, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Esters, Acyl Peroxides, Acyl Halides and other aspects.Reference of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On May 11, 2017, Li, Siyuan; Gui, Shaoxiao; Zhang, Jicheng; Huang, Luning; Tao, Anping; Gu, Hong published a patent.Computed Properties of 97859-49-9 The title of the patent was Preparation method for tedizolid and its intermediate. And the patent contained the following:

The present invention relates to a preparation method for a tedizolid compound in Formula I. In Formula I, R is selected from hydrogen, benzyl or benzyl substituted by a substituent, the substituent is selected from a group consisting of halogen, nitryl, C1-C6 alkyl, and C1-C6 alkoxy, and R1 is C1-C6 alkyl or C1-C6 alkyl substituted by halogen. The method comprises: generating a compound having a structure with formula II and a compound having a structure with formula III by a coupled reaction under the catalysis of a metal catalyst, a substituent of R being defined as above, where X is a leaving group, the leaving group comprising chlorine, bromine, iodine, sulfonyl oxy such as trifluoromethane sulfonic oxy, methylsulfonyl oxy and benzenesulfonyl oxy, or benzenesulfonyl oxy substituted by one or more substituents, the substituent being selected from a group consisting of halogen, C1-C6 alkyl, and C1-C6 alkoxy. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Computed Properties of 97859-49-9

The Article related to tedizolid preparation, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Computed Properties of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On May 10, 2017, Li, Siyuan; Gui, Shaoxiao; Zhang, Jicheng; Huang, Luning; Tao, Anping; Gu, Hong published a patent.Formula: C4H7NO3 The title of the patent was Preparation method for tedizolid and its intermediate. And the patent contained the following:

The invention relates to a preparation method for a tedizolid compound in Formula I. In Formula I, R is selected from hydrogen, benzyl or benzyl substituted by a substituent, the substituent is selected from a group consisting of halogen, nitryl, C1-C6 alkyl, and C1-C6 alkoxy, and R1 is C1-C6 alkyl or C1-C6 alkyl substituted by halogen. The method comprises: generating a compound having a structure with formula II and a compound having a structure with formula III by a coupled reaction under the catalysis of a metal catalyst, a substituent of R being defined as above, where X is a leaving group, the leaving group comprising chlorine, bromine, iodine, sulfonyl oxy such as trifluoromethane sulfonic oxy, methylsulfonyl oxy and benzenesulfonyl oxy, or benzenesulfonyl oxy substituted by one or more substituents, the substituent being selected from a group consisting of halogen, C1-C6 alkyl, and C1-C6 alkoxy. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Formula: C4H7NO3

The Article related to tedizolid preparation, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Formula: C4H7NO3

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On November 28, 2017, Lu, Hualong published a patent.Electric Literature of 97859-49-9 The title of the patent was Preparation of oxazolidinone compounds as antibiotic agents. And the patent contained the following:

The title compounds shown in general formula I [wherein, R1 is selected from the groups as 3-amino-pyrrolidin-1-yl, N-methyl-3-amino-piperidin-1-yl, (R)-3-aminohexahydroazepin-1-yl, N-methyl-piperazin-1-yl, 3-methyl-piperazin-1-yl, pyrrol-1-yl, 3-methylpyrrol-1-yl, etc.; R2 is selected from H, hydroxy, Me, halogen, etc.; R3 is selected form OH, NHCOCH3, etc.] or pharmaceutically acceptable salts or isomers thereof were prepared as antibiotic agents. For example, compound II was prepared in a multi-step synthesis. The inventive compound can be applied in preparing the drugs for treating microbial infection, and II showed antibacterial activities against both Staphylococcus aureus and Staphylococcus epidermidis with MIC values of 0.25 μg/mL. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Electric Literature of 97859-49-9

The Article related to preparation oxazolidinone antibiotic agent treatment human bacterial infection, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Electric Literature of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On July 3, 2014, Yang, Yushe; Guo, Bin; Li, Zhan; Li, Wei published a patent.Synthetic Route of 97859-49-9 The title of the patent was Benzoxazine-oxazolidinone compounds as antiinfective agents and their preparation, pharmaceutical compositions and use in the treatment of multidrug resistant bacterial infections. And the patent contained the following:

Disclosed are benzoxazine-oxazolidinone compounds of formula I and their optical isomers, pharmaceutically acceptable salts, preparation method and application in preparing drugs for treating an infectious disease and in particular, an infectious disease caused by multidrug resistant bacteria. Compounds of formula I wherein R1 is amino and derivatives, phosphonate, succinate, L-arginine; R2 is (un)branched alkyl; R3 is halo, CN, OH, amino and derivatives, etc.; and their optical isomers, pharmaceutically acceptable salts thereof, are claimed. Compounds of formula I were prepared by using cross-coupling as the key steps. All the invention compounds were evaluated for their antibacterial activity. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Synthetic Route of 97859-49-9

The Article related to benzoxazine oxazolidinone preparation antiinfective treatment multidrug resistant bacterial infection, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Synthetic Route of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On January 4, 2019, Peer Mohamed, Shahul Hameed; Bharatham, Nagakumar; Katagihallimath, Nainesh; Sharma, Sreevalli; Nandishaiah, Radha; Ramachandran, Vasanthi published a patent.SDS of cas: 97859-49-9 The title of the patent was Preparation of anti-bacterial heterocyclic compounds. And the patent contained the following:

The title compounds I [R1 = alkyl, cycloalkyl, alkylamino, etc.; R2 = H, F, Cl, etc.; R3 = H, alkyl, F, etc.; X1 = N or CR4 (wherein R4 = H, halo, cyano, etc.); X2 = N or CR5 (R5 = H, halo, cyano, etc.); X3 = N or CR6; and X4 = CR6 when dotted line represents a bond (R6 = H, cyano, alkyl, etc.); or X3 = CH2 or O; and X4 = CH2 when dotted line represents no bond; n = 0-2; Y1 and Y2 = (independently) N or CR7 (R7 = H, halo, cyano, etc.); Z1 = O, S, NH, CH2; R8 = H, OH, alkyl, F] along with their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms, and pharmaceutically active derivatives thereof, useful for killing or inhibiting the growth of a microorganism selected from the group consisting of bacteria, virus, fungi, and protozoa, were prepared E.g., a multi-step synthesis of (S)-II, starting 6-methoxy-1,5-naphthyridin-4-ol and chloro(chloromethyl)dimethylsilane, was described. Exemplified compounds I were tested for their antibacterial activity (data given). Pharmaceutical compositions comprising compound I, alone and in combination with at least one antibiotic, were disclosed. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).SDS of cas: 97859-49-9

The Article related to heterocyclic compound pyridooxazinone pyrazinooxazinone preparation antibacterial antiviral antifungal protozoacide, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.SDS of cas: 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On June 6, 2019, Mohamed, Shahul Hameed Peer; Bharatham, Nagakumar; Katagihallimath, Nainesh; Sharma, Sreevalli; Nandishaiah, Radha; Ramachandran, Vasanthi published a patent.Product Details of 97859-49-9 The title of the patent was Preparation of anti-bacterial heterocyclic compounds. And the patent contained the following:

The title compounds I [R1 = alkyl, cycloalkyl, alkylamino, etc.; R2 = H, F, Cl, etc.; R3 = H, alkyl, F, etc.; X1 = N or CR4 (wherein R4 = H, halo, cyano, etc.); X2 = N or CR5 (R5 = H, halo, cyano, etc.); X3 = N or CR6; and X4 = CR6 when dotted line represents a bond (R6 = H, cyano, alkyl, etc.); or X3 = CH2 or O; and X4 = CH2 when dotted line represents no bond; n = 0-2; Y1 and Y2 = (independently) N or CR7 (R7 = H, halo, cyano, etc.); Z1 = O, S, NH, CH2; R8 = H, OH, alkyl, F] along with their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms, and pharmaceutically active derivatives thereof, useful for killing or inhibiting the growth of a microorganism selected from the group consisting of bacteria, virus, fungi, and protozoa, were prepared E.g., a multi-step synthesis of (S)-II, starting 6-methoxy-1,5-naphthyridin-4-ol and chloro(chloromethyl)dimethylsilane, was described. Exemplified compounds I were tested for their antibacterial activity (data given). Pharmaceutical compositions comprising compound I, alone and in combination with at least one antibiotic, were disclosed. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Product Details of 97859-49-9

The Article related to heterocyclic compound pyridooxazinone pyrazinooxazinone preparation antibacterial antiviral antifungal protozoacide, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Product Details of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On September 12, 2009, Davies, Stephen G.; Elend, Dirk L.; Jones, Simon; Roberts, Paul M.; Savory, Edward D.; Smith, Andrew D.; Thomson, James E. published an article.Electric Literature of 168297-86-7 The title of the article was The dienolate aldol reaction of (E)-N-crotonoyl C(4)-isopropyl SuperQuat: asymmetric synthesis of α-vinyl-β-hydroxy carboxylic acid derivatives and conversion to α-ethylidene-β-hydroxy esters (β-substituted Baylis-Hillman products). And the article contained the following:

The synthesis of α-vinyl-β-hydroxy esters and α-ethylidene-β-hydroxy esters (β-substituted Baylis-Hillman products) via the dienolate aldol reaction of (E)-N-crotonoyl C(4)-iso-Pr SuperQuat is described. High levels of syn-diastereoselectivity (up to >98% de) are observed for the dienolate aldol reaction with boron enolates, generated either directly with Bu2BOTf or by transmetalation of the potassium enolate with B-bromocatecholborane. Cleavage of the resultant syn-aldol products from the auxiliary gives α-vinyl-β-hydroxy esters in >98% de and >98% ee. Subsequent isomerization of the double bond into conjugation provides α-ethylidene-β-hydroxy esters (β-substituted Baylis-Hillman products) in high diastereo- and enantiopurity (≥91:9 [(E):(Z)] and >98% ee). The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Electric Literature of 168297-86-7

The Article related to hydroxy ester vinyl ethylidene stereoselective preparation aldol crotonoyloxazolidinone, Aliphatic Compounds: Carboxylic Acids and Peroxycarboxylic Acids and Their Sulfur-Containing Analogs and Salts and other aspects.Electric Literature of 168297-86-7

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On September 22, 2010, Hiebel, Marie-Aude; Pelotier, Beatrice; Piva, Olivier published an article.Computed Properties of 168297-86-7 The title of the article was Stereoselective synthesis of the C1-C13 fragment of bistramide A. And the article contained the following:

The C1-C13 fragment I of bistramide A was prepared from 5-hexenoic acid in 15 linear steps and in 16% overall yield. The core 2,6-trans-tetrahydropyran ring was obtained via a kinetically controlled oxa-Michael cyclization from the corresponding chiral α,β-unsaturated hydroxyester. This precursor was prepared by using a diastereoselective alkylation reaction using Davies Superquat auxiliary and a diastereoselective Roush’s allylboration as key steps. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Computed Properties of 168297-86-7

The Article related to enantioselective synthesis bistramide a fragment michael cyclization alkylation, allylation chiral auxiliary enantioselective bistramide a fragment, Biomolecules and Their Synthetic Analogs: Others, Including Purines, Pyrimidine Nucleic Acid Bases, Flavins, Lignans and other aspects.Computed Properties of 168297-86-7

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On February 11, 2021, Harikrishnan, Lalgudi S.; Park, Peter Kinam; Ruan, Zheming; Wei, Donna D.; O’Malley, Daniel; Wan, Honghe; Purandare, Ashok Vinayak; Fink, Brian E. published a patent.COA of Formula: C4H7NO3 The title of the patent was Preparation of substituted benzamides as RORγ agonists for the treatment of cancer. And the patent contained the following:

The invention is directed to compounds of the formula I wherein X is N and CR5; R5 is H, CN, halo, etc.; Y is CR6; R6 is H, CN, halo, etc.; R1 is (CH2)0-2-NHCOO-(CRxRy)0-4-R1a,(CH2)0-2-NHCORx-(CRxRy)0-4-R1a, 4-10 membered heterocycle-(CRxRy)0-4-R1a, etc.; each Rx and Ry are independently H and C1-3 alkyl; R1a is H, CF3, OH, etc.; R2 and R3 are independently H, halo and C1-3 alkyl; R4 is C1-6 alkyl, C1-6 alkenyl, C1-6 haloalkyl, etc.; and stereoisomers and pharmaceutically acceptable salt thereof; their preparation and use for the treatment of cancer. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their RORγ agonistic activity. From the assay, it was determined that compound II exhibited EC50 value of 1.7 nM. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).COA of Formula: C4H7NO3

The Article related to benzamide preparation ror gamma agonist treatment cancer, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Amides, Amidines, Imidic Esters, Hydrazides, and Hydrazonic Esters and other aspects.COA of Formula: C4H7NO3

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem